| Feb. 26, 2004
Upper Michigan
Cancer Center seeks candidates for prostate cancer research
study
The Upper Michigan
Cancer Center at Marquette
General Hospital is working closely with the Southwest Oncology
Group to identify possible participants
in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) to determine
if those vitamins are effective in preventing prostate cancer.
The purpose of the investigative study — sponsored by the National Cancer
Institute (NCI) — is to determine if selenium and/or vitamin E can prevent
or reduce the occurrence of prostate cancer. A large study looking at the effects
of selenium on prostate cancer has never been done.
You may be able to participate in SELECT if you:
· are a male age 55 or older (50 or older for African-Americans)
· have never had prostate cancer
· have not had any other cancer for the last five years (except skin cancer)
· are in generally good health
· are not currently taking, or willing to stop taking, selenium and vitamin
E
· are not currently receiving anticoagulation therapy
· have no history of hemorrhagic stroke
Aside from skin cancer, prostate cancer is the cancer found
most often in U.S. men. Due to early detection, five-year survival
rates are high. However, even non-fatal prostate cancer can affect
your quality of life.
More than 32,000 men will take part in SELECT. Those deciding to participate
in the study will read and sign a consent form that explains SELECT in more
detail. All capsules are provided free of charge.
An informational screening with a free PSA (Prostate Specific Antigen) test
will be held from 10 a.m. to 2 p.m. on Friday, March 12, at Chippewa Medical
Associates in Sault Ste. Marie. Chippewa
Medical Associates is located at 510
Ashmun St., Suite 5.
Those interesting in participating are encouraged to call the Upper Michigan
Cancer Center
at 906-225-3500 or 1-800-562-9753, ext. 3500.
|
